[go: up one dir, main page]

CO6420340A2 - Derivados de benzofurano - Google Patents

Derivados de benzofurano

Info

Publication number
CO6420340A2
CO6420340A2 CO11106899A CO11106899A CO6420340A2 CO 6420340 A2 CO6420340 A2 CO 6420340A2 CO 11106899 A CO11106899 A CO 11106899A CO 11106899 A CO11106899 A CO 11106899A CO 6420340 A2 CO6420340 A2 CO 6420340A2
Authority
CO
Colombia
Prior art keywords
optionally substituted
ring
represent
hydrogen atom
lower alkyl
Prior art date
Application number
CO11106899A
Other languages
English (en)
Inventor
Tetsuya Tsukamoto
Takeshi Wakabayashi
Taiichi Ohra
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CO6420340A2 publication Critical patent/CO6420340A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención provee un compuesto representadopor la siguiente Fórmula (I):donde:El Anillo A representa un anillo de piperazina opcionalmente sustituido, un anillo de morfolina opcionalmente sustituido, o un anillo de homopiperazina opcionalmente sustituido;R1 y R2 son iguales o diferentes entre sí, y representan un átomo de hidrógeno o un alquilo inferior opcionalmente sustituido;R3 y R4 son iguales o diferentes entre sí, y representan un átomo de hidrógeno o un alquilo inferior halogenado o no halogenado;R5 a R7 son iguales o diferentes entre sí, y representan un átomo de hidrógeno, un átomo de halógeno, hidroxi, alquilo inferior opcionalmente sustituido, alquenilo interior opcionalmente sustituido, alcoxi inferior opcionalmente sustituido, grupo hidrocarbonado cíclico alifático opcionalmente sustituido, arilo opcionalmente sustituido, un anillo heterocíclico opcionalmente sustituido, amino opcionalmente sustituido, o acilo; yrepresenta un enlace simple o un enlace doble, o una sal del mismo.
CO11106899A 2009-03-10 2011-08-23 Derivados de benzofurano CO6420340A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009056719 2009-03-10

Publications (1)

Publication Number Publication Date
CO6420340A2 true CO6420340A2 (es) 2012-04-16

Family

ID=42224778

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11106899A CO6420340A2 (es) 2009-03-10 2011-08-23 Derivados de benzofurano

Country Status (37)

Country Link
US (4) US8957069B2 (es)
EP (2) EP2406243B1 (es)
JP (2) JP5746631B2 (es)
KR (1) KR20110128913A (es)
CN (2) CN103965147B (es)
AR (1) AR076098A1 (es)
AU (1) AU2010221979A1 (es)
BR (1) BRPI1009252A2 (es)
CA (1) CA2754904A1 (es)
CL (1) CL2011002206A1 (es)
CO (1) CO6420340A2 (es)
CR (1) CR20110474A (es)
CY (1) CY1115469T1 (es)
DK (1) DK2406243T3 (es)
DO (1) DOP2011000281A (es)
EA (1) EA201171020A1 (es)
EC (1) ECSP11011318A (es)
ES (1) ES2487616T3 (es)
HK (1) HK1202293A1 (es)
HR (1) HRP20140687T1 (es)
IL (1) IL214667A0 (es)
MA (1) MA33159B1 (es)
MX (1) MX2011009394A (es)
NZ (1) NZ594847A (es)
PE (1) PE20120357A1 (es)
PL (1) PL2406243T3 (es)
PT (1) PT2406243E (es)
RS (1) RS53416B (es)
SG (1) SG173757A1 (es)
SI (1) SI2406243T1 (es)
SM (1) SMT201500027B (es)
TN (1) TN2011000422A1 (es)
TW (1) TWI477497B (es)
UA (1) UA107657C2 (es)
UY (1) UY32481A (es)
WO (1) WO2010104194A1 (es)
ZA (1) ZA201106045B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA107657C2 (uk) * 2009-03-10 2015-02-10 Такеда Фармасьютікал Компані Лімітед Похідні бензофурану
JPWO2011062194A1 (ja) 2009-11-18 2013-04-04 武田薬品工業株式会社 アミノピリジン誘導体
MX2014009923A (es) 2012-02-20 2015-08-10 Basf Se Intensificación de la acción antimicrobiana de biocidas con polimeros.
US9816233B2 (en) * 2012-09-28 2017-11-14 Kimberly-Clark Worldwide, Inc. Hybrid fiber compositions and uses in containerboard packaging
US9908680B2 (en) 2012-09-28 2018-03-06 Kimberly-Clark Worldwide, Inc. Tree-free fiber compositions and uses in containerboard packaging
EP2903980B1 (en) * 2012-10-01 2017-07-19 F. Hoffmann-La Roche AG Benzimidazoles as cns active agents
KR101716099B1 (ko) * 2013-09-12 2017-03-13 에프. 호프만-라 로슈 아게 인돌-카복스아마이드 유도체
US11447471B2 (en) 2017-06-23 2022-09-20 Kyowa Kirin Co., Ltd. α,β-unsaturated amide compound
CN109580790A (zh) * 2017-09-28 2019-04-05 安徽省庆云医药股份有限公司 一种液相色谱法分离测定西洛多辛及其光学异构体的方法
CN108530405A (zh) * 2018-05-08 2018-09-14 南京晓庄学院 非金属路易斯酸催化烯烃分子内加成c-o键合成苯并呋喃衍生物的方法
CN109879839B (zh) * 2019-03-12 2023-04-25 沈阳大学 6-哌嗪甲基-7-羟基苯并呋喃类化合物及其医药用途
CN113045523B (zh) * 2019-12-27 2022-09-23 上海泓博智源医药股份有限公司 一种咪唑啉吡啶化合物中间体的制备方法
UY39129A (es) * 2020-03-16 2021-10-29 Novartis Ag Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CN111362965B (zh) * 2020-04-27 2022-05-03 梯尔希（南京）药物研发有限公司 一种莫西菌素杂质的制备方法
CN113219085B (zh) * 2021-03-31 2022-05-13 河北国龙制药有限公司 一种2,3-二甲基溴苯有关物质的检测方法
CN113214205B (zh) * 2021-04-09 2022-06-10 南方海洋科学与工程广东省实验室(湛江) 一种色原酮衍生物的制备方法
CN115260136B (zh) * 2022-08-09 2023-08-15 嘉兴学院 一种苯酞类化合物及其制备方法
CN115724721A (zh) * 2022-12-19 2023-03-03 山东京博石油化工有限公司 一种2-取代基-4-溴苯酚的制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0106800A1 (de) 1982-10-08 1984-04-25 Ciba-Geigy Ag Furane
JPH04149546A (ja) 1990-10-15 1992-05-22 Konica Corp 有機着色物質の光褪色防止方法
TW199152B (es) 1990-11-01 1993-02-01 Takeda Pharm Industry Co Ltd
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
DE4333254A1 (de) 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
US6319498B1 (en) 1995-03-14 2001-11-20 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
DE19514567A1 (de) 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
WO1998008868A1 (en) 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS
JP4149546B2 (ja) 1996-12-24 2008-09-10 株式会社東芝 半導体装置の製造方法
JPH1149765A (ja) * 1997-06-05 1999-02-23 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
CA2291026A1 (en) 1997-06-05 1998-12-10 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
AU736596B2 (en) 1997-07-25 2001-08-02 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
DE69915508T2 (de) 1998-12-04 2005-01-27 Takeda Chemical Industries, Ltd. Benzofuranderivate, verfahren zu ihrer herstellung und deren verwendungen
DE19932314A1 (de) 1999-07-10 2001-01-11 Merck Patent Gmbh Benzofuranderivate
MXPA02000973A (es) 1999-07-29 2002-07-30 Lilly Co Eli Benzofurilpiperazinas y benzofurilhomopiperazinas: agonistas de serotonina.
DE19958496A1 (de) 1999-12-04 2001-06-07 Merck Patent Gmbh Verfahren zur Herstellung von 5-(1-Piperazinyl)-benzofuran-2-carboxamid durch Übergangsmetallkatalysierte Aminierung
US20040094431A1 (en) * 2000-06-12 2004-05-20 Howard A. Fromson Brush graining
AU2001292350A1 (en) 2000-10-05 2002-04-15 Takeda Chemical Industries Ltd. Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells
ATE527247T1 (de) 2001-07-05 2011-10-15 Takeda Pharmaceutical Benzokondensierte 5gliedrige heterocyclische verbindungen, verfahren zu deren herstellung und deren verwendung
CA2477903C (en) * 2002-03-01 2010-10-12 Takeda Chemical Industries, Ltd. Substituted benzofurans useful as protein kinase b activators
JP4580653B2 (ja) 2002-04-02 2010-11-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換されたアミノイソオキサゾリン誘導体および抗鬱薬としてのそれらの使用
EP1350769A1 (de) * 2002-04-04 2003-10-08 Bystronic Maschinen AG Vorrichtung und Verfahren zum Teilen von vertikalen Glasplatten
CA2495383A1 (en) 2002-08-12 2004-02-26 Takeda Pharmaceutical Company Limited Fused benzene derivative and use
TWI355381B (en) 2003-04-23 2012-01-01 Schering Corp 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-tri
CA2525713A1 (en) 2003-05-20 2004-12-29 Genentech, Inc. Benzofuran inhibitors of factor viia
DE10326939A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
KR101138673B1 (ko) 2003-06-26 2012-04-24 다케다 야쿠힌 고교 가부시키가이샤 칸나비노이드 수용체 조절제
JP3678733B2 (ja) * 2003-10-03 2005-08-03 株式会社エヌ・ティ・ティ・ドコモ 携帯通信端末及び位置情報提供方法
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050095401A1 (en) * 2003-11-04 2005-05-05 Fuji Photo Film Co., Ltd. Image recording material and depression-and-protrusion forming method
CA2558019A1 (en) 2004-03-22 2005-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Alpha-trifluoromethyl alcohols or amines as glucocorticoid mimetics
CA2563635A1 (en) 2004-04-21 2005-11-03 Schering Corporation Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
DE102004063797A1 (de) * 2004-12-30 2006-07-13 Schwarz Pharma Ag Sauerstoffhaltige annelierte Phenylpiperazin- und Phenyldiazepancarboxamide
AU2006237354B2 (en) * 2005-04-21 2012-03-01 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidines for the treatment of inflammatory diseases
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
KR20090004976A (ko) 2006-04-19 2009-01-12 아스테라스 세이야쿠 가부시키가이샤 아졸카르복사미드 유도체
GB0707000D0 (en) 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
HU230729B1 (hu) 2007-05-30 2017-12-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Új, szelektív 5HT7-receptorgátló benzofurán-származékok és eljárás előállításukra
US8382180B2 (en) * 2007-10-31 2013-02-26 Applied Material, Inc. Advanced FI blade for high temperature extraction
CA2717138A1 (en) 2008-03-05 2009-09-11 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compounds and bicyclic heteroaryl having glucagon antagonistic action useful for treating diabetes
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
UA107657C2 (uk) 2009-03-10 2015-02-10 Такеда Фармасьютікал Компані Лімітед Похідні бензофурану

Also Published As

Publication number Publication date
UY32481A (es) 2010-09-30
CN103965147A (zh) 2014-08-06
US20120232095A1 (en) 2012-09-13
PL2406243T3 (pl) 2014-10-31
CR20110474A (es) 2011-12-01
SG173757A1 (en) 2011-09-29
MX2011009394A (es) 2011-10-11
CA2754904A1 (en) 2010-09-16
JP5841651B2 (ja) 2016-01-13
CL2011002206A1 (es) 2012-02-03
JP5746631B2 (ja) 2015-07-08
AR076098A1 (es) 2011-05-18
SMT201500027B (it) 2015-05-05
US20120232096A1 (en) 2012-09-13
EP2406243A1 (en) 2012-01-18
EP2781513A1 (en) 2014-09-24
CN102421767A (zh) 2012-04-18
BRPI1009252A2 (pt) 2016-03-15
CY1115469T1 (el) 2017-01-04
MA33159B1 (fr) 2012-03-01
SI2406243T1 (sl) 2014-08-29
HK1202293A1 (en) 2015-09-25
UA107657C2 (uk) 2015-02-10
RS53416B (en) 2014-12-31
DOP2011000281A (es) 2011-10-31
US8957069B2 (en) 2015-02-17
DK2406243T3 (da) 2014-07-21
IL214667A0 (en) 2011-09-27
WO2010104194A1 (en) 2010-09-16
KR20110128913A (ko) 2011-11-30
JP2015044848A (ja) 2015-03-12
CN103965147B (zh) 2016-08-24
TN2011000422A1 (en) 2013-03-27
ZA201106045B (en) 2012-10-31
NZ594847A (en) 2013-10-25
EP2406243B1 (en) 2014-05-07
PE20120357A1 (es) 2012-05-03
ES2487616T3 (es) 2014-08-22
US20120046277A1 (en) 2012-02-23
PT2406243E (pt) 2014-07-11
TWI477497B (zh) 2015-03-21
US8288390B2 (en) 2012-10-16
CN102421767B (zh) 2014-06-18
AU2010221979A1 (en) 2011-09-15
TW201036960A (en) 2010-10-16
US20100234357A1 (en) 2010-09-16
JP2012520238A (ja) 2012-09-06
ECSP11011318A (es) 2011-10-31
HRP20140687T1 (hr) 2014-10-24
EA201171020A1 (ru) 2012-03-30

Similar Documents

Publication Publication Date Title
CO6420340A2 (es) Derivados de benzofurano
CY1118435T1 (el) Παραγωγο μορφολινο νουκλεϊνικου οξεος
PH12014500434A1 (en) New dihydroquinoline-2-one derivatives
CO2017001178A2 (es) Derivado de piridona que tiene un grupo tetrahidropiranil metilo
MX2015010775A (es) Benzoxazoles sustituidos y metodos para usarlos.
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
ECSP11010912A (es) Compuestos de pirrol
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
PE20160523A1 (es) Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
CY1117688T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
BR112013018732A2 (pt) novos derivados de amida de aril-benzocicloalquila
ECSP11011218A (es) Herbicidas derivados de ciclopentanodiona.
MY161134A (en) Piperazine compound having a pgds inhibitory effect
CY1124908T1 (el) Παραγωγο μορφινανης
ECSP13012535A (es) Compuesto heterocíclico y sus usos
ES2578628T3 (es) Compuestos de L-dihidro-2-oxoquinolina como ligandos del receptor de 5-HT4
CO6420347A2 (es) Derivados de imidazotiazol que tienen estructura de anillo de prolina
CY1117560T1 (el) Νεο υποκατασταθεν παραγωγο ισοκινολινης
CY1117026T1 (el) Ετεροκυκλικες ενωσεις για αντιμετωπιση ή προληψη διαταραχων που προκαλουνται απο μειωμενη νευροδιαβιβαση σεροτονινης, νορεπινεφρινης ή ντοπαμινης
CO2017003830A2 (es) Compuestos de piridina
CO6460700A2 (es) Compuesto de pirazol
CY1117348T1 (el) Νεο παραγωγο φαινυλπυριδινης και φαρμακο που περιεχει αυτο
CY1115355T1 (el) Παραγωγο του οξειδιου του βενζοθειοφαινιου και αλας αυτου
IN2014DE00237A (es)

Legal Events

Date Code Title Description
FG Application granted